Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,291 active trials259 approved drugs3,814 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics524
Variants & evidence3814
Drugs427
Trials91377
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,583)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,701–3,725 of 4,583 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma.
· Genes Chromosomes Cancer · 2013 · PMID 23463663 · validated civic_curation pubmed
Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma.
· Mod Pathol · 2019 · PMID 31189996 · validated civic_curation pubmed
EWSR1-PATZ1-rearranged sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers.
· Mod Pathol · 2021 · PMID 33012788 · validated civic_curation pubmed
Sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases.
· Mod Pathol · 2024 · PMID 38043789 · validated civic_curation pubmed
Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion.
· Front Oncol · 2020 · PMID 32266142 · validated civic_curation pubmed
Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases.
· Histopathology · 2021 · PMID 33382123 · validated civic_curation pubmed
Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease: A Study of 4 Aggressive Cases With Clinical, Pathologic, Molecular, and Radiologic Findings.
· Am J Surg Pathol · 2021 · PMID 33949344

Showing 3,701–3,725 of 4,583 publications

← Previous
1
…
148
149
150
…
184
Next →

· validated civic_curation

Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.

· Genes (Basel) · 2020 · PMID 32668764 · validated civic_curation pubmed

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.

· Heliyon · 2023 · PMID 38074875 · validated civic_curation pubmed

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.

· Oncologist · 2025 · PMID 39504576 · validated civic_curation pubmed

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.

· Oncologist · 2024 · PMID 38470950 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL.

· Leukemia · 2023 · PMID 36810896 · validated civic_curation pubmed

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

· Mol Cancer Ther · 2008 · PMID 18375819 · validated civic_curation pubmed

NRAS-mutant melanoma: response to chemotherapy.

· Arch Dermatol · 2011 · PMID 21576590 · validated civic_curation pubmed

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

· J Thorac Oncol · 2013 · PMID 23524406 · validated civic_curation pubmed

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

· Leukemia · 2014 · PMID 25212276 · validated civic_curation pubmed

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

· J Thorac Oncol · 2013 · PMID 23584301 · validated civic_curation pubmed

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

· Pigment Cell Melanoma Res · 2013 · PMID 23890088 · validated civic_curation pubmed

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

· Oncotarget · 2015 · PMID 26423602 · validated civic_curation pubmed

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

· Nat Med · 2014 · PMID 24836576 · validated civic_curation pubmed

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.

· J Thorac Oncol · 2016 · PMID 26724472 · validated civic_curation pubmed

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

· Lung Cancer · 2014 · PMID 24192513 · validated civic_curation pubmed

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.

· Front Pharmacol · 2014 · PMID 24782778 · validated civic_curation pubmed